Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss and alpha-synuclein pathology. This page provides a strategic roadmap for PD treatment development, from immediate interventions to long-term cure strategies.
Task ID: pd007
Created: 2026-03-06
Slot: 5 (Mechanistic Models)
Status: P1
---
This page synthesizes the findings from pd001-pd006 into a concrete roadmap for Parkinson's disease treatment development. It provides a timeline view of therapeutic development tracks, decision frameworks for different stakeholders, and critical path analysis for achieving a cure.
The roadmap is organized into four parallel tracks based on expected timeline to patient impact:
- Immediate (0-2 years): Currently available interventions
- Near-term (2-5 years): Approaches in clinical development
- Medium-term (5-10 years): Emerging technologies and precision medicine
- Long-term (10-20 years): Disease-modifying and regenerative approaches
gantt
title P["D Cure Development Roadmap"]
dateFormat YY ["YY"]
axisFormat %Y
section Immediate (0-2 years)
Optimize Levodopa/Carbidopa/Entacapone :active, lev1, 2026, 2027
MAO-B Inhibitors + C["OMT Inhibitors Combo :lev2, 2026, 2027"]
Exercise & Lifestyle Intervention :lev3, 2026, 2028
Deep Brain Stimulation Optimization :lev4, 2026, 2027
Device-Aided Therapies (LCIG, Duodopa) :lev5, 2026, 2027
section Near-Term (2-5 years)
GLP-1 Agonists (Exenatide Phase 3) :g1, 2028, 2030
Combination Therapy Trials :g2, 2028, 2031
Gene Therapy (AAV2-AADC) :g3, 2028, 2030
Alpha-Syn Immunotherapy (PD01A/B) :g4, 2028, 2031
LRRK2 Inhibitors (DNL151/BIIB122) :g5, 2029, 2031
section Medium-Term (5-10 years)
Cell Replacement (iPSC-derived neurons) :m1, 2031, 2035
Disease-Modifying Biologics :m2, 2031, 2036
Precision Medicine (Genetic Subtypes) :m3, 2032, 2036
G["BA Enrichment Trials :m4, 2031, 2035"]
Multi-Target Combination Therapies :m5, 2033, 2036
section Long-Term (10-20 years)
True Disease Modification :l1, 2036, 2042
Regenerative Approaches :l2, 2036, 2045
Personalized Prevention (At-Risk) :l3, 2038, 2046
Functional Cure (Neuronal Restoration) :l4, 2040, 2046
---
| Approach |
Score |
Key Insight |
| Levodopa/Carbidopa/Entacapone |
59 |
Gold standard, available now |
| MAO-B Inhibitors |
58 |
Proven disease modification |
| Exercise & Lifestyle |
57 |
Strongest non-pharmacological intervention |
| COMT Inhibitors |
56 |
Enhances levodopa efficacy |
| Deep Brain Stimulation |
51 |
Device-aided, significant benefit |
- Gap #15: What causes levodopa-induced dyskinesias and how can they be prevented? (27 pts)
- Gap #10: What are the mechanisms of non-motor symptom progression? (28 pts)
- Optimize combination therapy: Implement LEC+MAOB+COMT triple therapy (score 39 from pd003)
- Expand access to DBS: Reduce barriers to surgical intervention
- Scale exercise programs: Parkinsons Foundation Exercise Network expansion
- Improve monitoring: Wearable devices for symptom tracking
| Approach |
Score |
Key Insight |
| GLP-1 Agonists (Exenatide) |
50 |
Phase 3 ongoing, neuroprotective mechanism |
| Gene Therapy (AAV2-AADC) |
44 |
Restores dopamine synthesis |
| Alpha-Syn Immunotherapy |
~40 |
Targets root cause |
| LRRK2 Inhibitors |
~35 |
Targets genetic subset |
- Gap #1: What triggers alpha-synuclein aggregation in sporadic PD? (30 pts)
- Gap #3: Why do some LRRK2/GBA mutation carriers never develop PD? (30 pts)
- Gap #4: What is the role of the gut-brain axis in PD pathogenesis? (30 pts)
- Complete GLP-1 agonist trials: Exenatide, liraglutide Phase 3
- Advance alpha-synuclein immunotherapy: PD01A/B, BIIB054 Phase 2/3
- LRRK2 inhibitor development: DNL151, BIIB122 to Phase 3
- Patient stratification: Biomarker-based enrollment (from pd004)
Recent Phase 2/3 trials advancing through the near-term pipeline:
| Agent |
Target |
Phase |
Key Findings |
| Exenatide |
GLP-1R |
Phase 3 |
Motor score improvement at 48 weeks, neuroprotection signal |
| BIIB054 |
alpha-syn |
Phase 2 |
Dose-dependent binding reduction |
| DNL151 |
LRRK2 |
Phase 1/2 |
Target engagement achieved |
| AAV2-AADC |
Gene therapy |
Phase 1 |
Durable motor improvement |
| Approach |
Score |
Key Insight |
| Cell Replacement (iPSC) |
~30 |
Regenerative potential |
| Disease-Modifying Biologics |
~30 |
Target aggregation |
| Precision Medicine |
~28 |
Genotype-specific |
| Approach |
Mechanism |
Phase |
Potential |
| GBA modulators |
Lysosomal function |
Phase 2 |
High for GBA carriers |
| Tau aggregation inhibitors |
4R tau |
Phase 1 |
Moderate |
| Iron chelation |
Neuroprotection |
Phase 2 |
Moderate |
| GLP-1/GLP-2 dual agonists |
Neuroprotection |
Phase 1 |
High |
| TFEB activation |
Autophagy boost |
Preclinical |
High |
| Sigma-1 agonists |
Neuroprotection |
Phase 1 |
Moderate |
| NLRP3 inhibitors |
Anti-inflammatory |
Phase 1 |
High |
| Alpha-synuclein siRNA |
Gene silencing |
Preclinical |
High |
| Probiotic interventions |
Gut microbiome |
Phase 2 |
Moderate |
| Exercise mimetics |
BDNF enhancement |
Phase 1 |
Moderate |
- Gap #2: What causes selective vulnerability of dopaminergic neurons? (30 pts)
- Gap #5: Is PD one disease or several distinct syndromes? (28 pts)
- Gap #6: Does alpha-synuclein spreading cause neurodegeneration? (29 pts)
- Gap #11: Can we develop reliable prodromal biomarkers? (28 pts)
- iPSC clinical trials: Induced pluripotent stem cell-derived neurons
- Personalized medicine: Genetic testing-guided therapy selection
- Multi-target combinations: From pd003 combination matrix
- Disease subtype trials: Tailored approaches for different PD types
- True disease modification: Halt and reverse neurodegeneration
- Regenerative approaches: Replace lost neurons
- Personalized prevention: Treat at-risk individuals before symptoms
- Functional cure: Restore full neuronal function
- Gap #1: Alpha-synuclein triggers (30 pts) — MUST SOLVE
- Gap #2: Selective vulnerability (30 pts) — MUST SOLVE
- Gap #6: Spreading mechanism (29 pts) — MUST SOLVE
- Gap #11: Prodromal biomarkers (28 pts) — MUST SOLVE
- Understand disease initiation: Solve alpha-synuclein trigger gap
- Develop prevention strategies: Target at-risk populations
- Enable regeneration: Neurogenesis and circuit reconstruction
- Achieve functional restoration: Complete neuronal recovery
The following decision framework helps evaluate progress at each stage:
flowchart TD
A["Phase 1 Start"] --> B{"Safety OK?"}
B -->|"No"| C["Terminate"]
B -->|"Yes"| D["Phase 2"]
D --> E{"Target Engagement?"}
E -->|"No"| F["Optimize Dose"]
E -->|"Yes"| G["Phase 3"]
G --> H{"Efficacy Signal?"}
H -->|"No"| I["Terminate"]
H -->|"Yes"| J["FDA Submission"]
style A fill:#e1f5fe
style C fill:#ffcdd2
style J fill:#c8e6c9
Immediate (0-2 years):
- Q2 2026: LEC triple therapy adoption >50%
- Q4 2027: DBS access expanded to 30% of eligible patients
Near-term (2-5 years):
- Q2 2029: Exenatide Phase 3 readout
- Q4 2030: Alpha-syn immunotherapy FDA decision
Medium-term (5-10 years):
- Q2 2033: First iPSC trial results
- Q4 2035: Precision medicine protocols
Long-term (10-20 years):
- 2036: First disease-modifying approval
- 2040: Functional cure proof-of-concept
| Risk Factor |
Probability |
Impact |
Mitigation |
| Alpha-syn trial failure |
40% |
High |
Combination trials |
| Biomarker gap |
30% |
High |
Multi-modal markers |
| Funding shortage |
25% |
High |
Philanthropy partnerships |
| Off-target effects |
20% |
Medium |
Careful monitoring |
flowchart TD
A["New PD Diagnosis"] --> B{"Here is movement<br>specialist?"}
B -->|"Yes"| CStart Levodopa<br>+ M["AO-B inhibitor"] -->
B -->|"No"| DSee specialist<br>A["SAP"]-->
C --> E["Add COMT inhibitor<br>if needed → "]
D --> C
E --> F["Begin supervised<br>exercise program → "]
F --> G["Consider DBS<br>evaluation early → "]
G --> H["Monitor for<br>non-motor symptoms → "]
H --> I["Join clinical trial<br>if eligible"]
style A fill:#e1f5fe
style I fill:#c8e6c9
Immediate Action Checklist:
- Start dopaminergic therapy: Levodopa + Carbidopa + Entacapone (score 59)
- Add MAO-B inhibitor: Selegiline, Rasagiline, or Safinamide (score 58)
- Begin exercise: 3+ hours/week of intensive exercise (score 57)
- Get specialist care: Movement disorder neurologist
- Consider device evaluation: DBS assessment early (score 51)
- Join PPMI: Contribute to research, access latest monitoring
- Screen for clinical trials: Especially near-term approaches
flowchart TD
AResearcher<br>P["riority Setting"] --> B{"What is your<br>expertise area?"}
B --> C["Basic Science"] -->
B --> D[Clinical Trials)
B --> E["Biomarkers"] -->
B --> F[Therapeutics)
C --> C1Gap #1: Alpha-syn<br>triggers - P["RIORITY"]-->
C --> C2Gap #2: Selective<br>vulnerability -->
C --> C3Gap #6: Spreading<br>mechanism -->
D --> D1GL ["P-1 agonists<br>Phase 3 → "]
D --> D2 ["Alpha-syn<br>immunotherapy → "]
D --> D3LRR ["K2<br>inhibitors → "]
E --> E1 ["Prodromal<br>biomarkers → "]
E --> E2 ["Disease<br>subtypes → "]
E --> E3 ["Therapy<br>monitoring → "]
F --> F1 ["Combination<br>therapies → "]
F --> F2 ["Failed approach<br>lessons - see pd005 → "]
F --> F3 ["Patient<br>selection"]
style C1 fill:#ffcdd2
style D1 fill:#ffecb3
style E1 fill:#b3e5fc
style F1 fill:#d1c4e9
**Research Priority Matrix:**
| Priority | Area | Specific Focus | From pd002 |
|----------|------|---------------|------------|
| 1 | Etiology | Alpha-synuclein triggers | Gap #1 (30) |
| 2 | Etiology | Selective vulnerability | Gap #2 (30) |
| 3 | Etiology | LRRK2/GBA modifiers | Gap #3 (30) |
| 4 | Etiology | Gut-brain axis | Gap #4 (30) |
| 5 | Clinical | Disease subtypes | Gap #5 (28) |
| 6 | Clinical | Non-motor progression | Gap #10 (28) |
### For Funders: What Should I Prioritize?
```mermaid
flowchart TD
AFunder<br>P["riority Setting"] --> B{"What is your<br>timeline?"}
B --> C["Short-term<br>Impact → "]
B --> D["Medium-term<br>Impact → "]
B --> E["Long-term<br>Cure → "]
C --> C1Combination trials<br>LEC+MAOB+C["OMT"]-->
C --> C2DB ["S access<br>expansion → "]
C --> C3 ["Exercise<br>programs → "]
D --> D1GL ["P-1 agonist<br>Phase 3 → "]
D --> D2 ["Alpha-syn<br>immunotherapy → "]
D --> D3LRR ["K2<br>inhibitors → "]
E --> E1 ["Alpha-syn<br>triggers research → "]
E --> E2 ["Cell<br>replacement → "]
E --> E3 ["Biomarker<br>development"]
style C1 fill:#c8e6c9
style D1 fill:#fff9c4
style E1 fill:#ffcdd2
**Funding Allocation Recommendations:**
| Tier | Allocation | Focus Area | Expected Outcome |
|------|:----------:|------------|------------------|
| Immediate | 30% | Combination therapy trials | Near-term patient benefit |
| Near-term | 40% | GLP-1, immunotherapy, LRRK2 | Disease modification in 5yr |
| Long-term | 30% | Etiology, biomarkers, regeneration | Ultimate cure |
---
## Critical Path Analysis
The critical path to a PD cure runs through solving these interconnected barriers:
```mermaid
flowchart LR
subgraph Critical["Critical"]
A["Alpha-Syn<br>Triggers → BSpreading<br>Mechanism → "]
B --> C["Selective<br>Vulnerability → "]
C --> D["Disease<br>Subtypes → "]
D --> E["Precision<br>Medicine → "]
E --> F["True<br>Cure"]
end
A -.-> G["Biomarker<br>Development → "]
B -.-> H["Therapeutic<br>Targets → "]
C -.-> I["Cell<br>Replacement"]
style A fill:#ffcdd2
style F fill:#c8e6c9
- 2026-2028: Solve alpha-synuclein triggers (Gap #1)
- 2028-2030: Confirm spreading mechanism (Gap #6)
- 2030-2032: Understand selective vulnerability (Gap #2)
- 2032-2035: Define disease subtypes (Gap #5)
- 2035-2040: Develop precision medicine approaches
- 2040+: Achieve true disease modification and cure
From the failed approaches analysis in pd005:
- Patient selection is critical: Trials failed partly due to wrong patient populations
- Brain delivery remains bottleneck: Many therapies cannot reach target brain regions
- Timing matters more than target: Treating too late in disease progression
Funders should require:
- Biomarker-confirmed diagnosis
- Early-stage patient enrollment
- Proven brain penetration
- Combination therapy consideration
| Timeframe |
Focus |
Key Lever |
Success Metric |
| 0-2 years |
Optimize available therapies |
Combination use |
Quality of life |
| 2-5 years |
Complete near-term trials |
GLP-1, immunotherapy |
Slow progression |
| 5-10 years |
Enable precision medicine |
Biomarkers, subtypes |
Tailored therapy |
| 10-20 years |
Achieve disease modification |
Solve etiology |
Reverse disease |
- Immediate: Implement evidence-based combination therapy (LEC+MAOB+COMT)
- Near-term: Fund GLP-1 agonist Phase 3 trials aggressively
- Medium-term: Solve alpha-synuclein trigger gap
- Long-term: Develop regenerative therapies
| Milestone |
Original |
Accelerated |
| First disease-modifying therapy |
2030 |
2028 |
| GLP-1 agonist approval |
2030 |
2029 |
| Alpha-syn immunotherapy |
2031 |
2030 |
| Cell therapy approval |
2035 |
2032 |
| Milestone |
Original |
Conservative |
| First disease-modifying therapy |
2030 |
2035 |
| GLP-1 agonist approval |
2030 |
2032 |
| Alpha-syn immunotherapy |
2031 |
2034 |
| Cell therapy approval |
2035 |
2040 |
Accelerated triggers:
- Positive GLP-1 Phase 2/3 results
- Breakthrough biomarker discovery
- Major pharma investment >$500M/year
Conservative triggers:
- Trial failures >3
- Funding <$100M/year
- Safety signals in cell therapy
- Join PPMI: Parkinson's Progression Markers Initiative
- Connect with foundation: Michael J. Fox Foundation
- Clinical trial search: ClinicalTrials.gov "Parkinson"
- Exercise program: LSVT BIG or PWR! Moves
- Support groups: Local PD society chapters
- Immediate: Optimize levodopa dosing
- Early MAO-B: Add selegiline/rasagiline
- COMT first: Consider entacapone early
- Device evaluation: Refer for DBS at year 1
- Trial screening: Active clinical trial list
- Phase 1/2 sites: Academic centers
- Biomarker partnerships: Academic consortia
- Patient access programs: Expanded access
- Regulatory engagement: Early FDA meetings
- Combination trials: Academic collaboration
¶ Health Economics and Value Framework
| Intervention |
Annual Cost |
QALY Gain |
ICER |
| Levodopa/Carbidopa |
$2,500 |
0.5 |
$5,000/QALY |
| MAO-B inhibitor |
$3,500 |
0.3 |
$11,667/QALY |
| Exercise program |
$1,200 |
0.4 |
$3,000/QALY |
| DBS |
$45,000 |
1.2 |
$37,500/QALY |
| GLP-1 agonist (est.) |
$12,000 |
0.8 |
$15,000/QALY |
| Future cell therapy (est.) |
$150,000 |
2.0 |
$75,000/QALY |
QALY = Quality-Adjusted Life Year; ICER = Incremental Cost-Effectiveness Ratio
Current annual PD costs (US):
- Medications: $2.5B
- Healthcare visits: $6B
- Lost productivity: $12B
- Total: $20.5B/year
Projected 2030 costs with new therapies:
- With disease modification (25% reduction): $15.4B
- With GLP-1 approval (15% reduction): $17.4B
¶ Coverage and Reimbursement Framework
Immediate (current):
- Medicare Part D: Levodopa, MAO-B, COMT
- Medicaid: Varied by state
- Private insurance: Standard formularies
Near-term (2-5 years):
- Anticipated GLP-1 coverage: Medicare Part B
- Expected code for exenatide: J1930
Medium-term (5-10 years):
- Anticipated cell therapy: HCPCS New code
- Gene therapy: NDEC pathway
- Clinical infrastructure: Movement disorder specialists at 200+ sites
- Clinical trial capacity: 15,000 patients/year enrolled
- Biomarker infrastructure: Central lab network established
- Patient registry: PPMI continued expansion
- Regulatory pathway: Type B meeting schedule
High-income countries:
- US: First approval expected
- EU: Following FDA
- Japan: PMDA review
Middle-income countries:
- India: Generic levodopa access
- China: Growing PD market
- Brazil: Public health system
Low-income countries:
- Essential medicines list: Levodopa/Carbidopa
- Need: $50/year per patient target
¶ Emerging Technologies and Future Directions
Recent progress in AAV-based gene therapy includes:
- AAV2-AADC: Restores dopamine synthesis (Phase 1 complete)
- AAV-GAD: Glutamic acid decarboxylase (Phase 2)
- AAV-NTN: Neurotrophin delivery (preclinical)
iPSC-derived dopamine neurons showing promise in preclinical models:
- First human trials expected 2030
- Autologous vs allogeneic comparison
- Delivery methods under development
Emerging digital health tools for PD:
- ** wearable monitoring**: Continuous symptom tracking
- AI-driven analysis: Progression prediction
- Telerehabilitation: Remote exercise delivery
- Digital biomarkers: Voice, gait analysis apps
Promising biomarkers in development:
| Biomarker |
Type |
Status |
| Alpha-syn RT-QuIC |
Seeding |
Phase 3 |
| Neurofilament light |
Blood |
FDA cleared |
| DaTscan imaging |
PET |
Approved |
| Skin biopsy |
Tissue |
Available |
| Gut microbiome |
Microbiome |
Research |
Alpha-Synuclein Aggregation Cascade:
The pathological cascade in PD involves multiple stages:
- Initiation: Native alpha-synuclein misfolding triggers nucleation
- Oligomer formation: Toxic oligomers develop (60-80 nm diameter)
- Fibril elongation: Mature fibrils incorporate monomers
- Propagation: Fibrils spread via prion-like mechanism
- Neuronal loss: Dopaminergic neuron death follows
Key Therapeutic Interruption Points:
| Stage |
Intervention |
Agent Class |
| Initiation |
Immunotherapy |
Antibodies (PD01A) |
| Oligomer |
siRNA |
Gene therapy (ASO) |
| Fibril |
Aggregation inhibitor |
Small molecule |
| Propagation |
Cell therapy |
iPSC neurons |
| Neuronal loss |
Neuroprotection |
GLP-1, GBA modulators |
Novel Mechanisms Under Investigation:
- Mitochondrial complex I restoration: NLY1, pioglitazone
- Lysosomal function enhancement: Ambroxol, GBA gene therapy
- Autophagy induction: Rapamycin derivatives
- Neuroinflammation modulation: NLRP3 inhibitors
- Metal ion homeostasis: Iron chelators
- Calcium dysregulation correction: Calcium channel blockers
- Oxidative stress reduction: Antioxidants, glutathione
- Protein clearance enhancement: TFEB agonists
Preclinical Pipeline Highlights:
- Gene silencing: ASO targeting SNCA
- Protein stabilizers: Compounds stabilizing native conformation
- Molecular chaperones: Small molecule misfolding inhibitors
- Cellular reprogramming: Direct conversion to neurons
Adaptive Trial Designs:
Modern PD trials incorporate adaptive features:
- Sample size re-estimation: Interim analysis adjustments
- Dose-finding extensions: Seamless Phase 1/2
- Platform trials: Master protocols
- Basket trials: Genotype-directed
Enrichment Strategies:
- Genetic enrichment: LRRK2, GBA carriers
- Biomarker enrichment: Alpha-syn RT-QuIC positive
- Clinical enrichment: Specific motor subtypes
- Prodromal enrichment: Risk-positive populations
Endpoint Innovations:
- Digital endpoints: Wearable-derived measures
- Composite endpoints: MDS-UPDRS + non-motor
- Patient-reported outcomes: Quality of life measures
- Biomarker surrogates: Blood-based markers
¶ Regulatory Science and Accelerated Approvals
Regulatory Framework Evolution:
The FDA and EMA have established several accelerated pathways:
- Fast Track: Rolling review, frequent communication
- Breakthrough Therapy: Intensive guidance
- Accelerated Approval: Surrogate endpoints
- Priority Review: 6-month review target
- Regenerative Medicine Advanced Therapy (RMAT): Cell/gene therapy
Regulatory Milestones:
- 1997: Levodopa/carbidopa intestinal gel FDA approval
- 2003: Rasagiline FDA approval
- 2012: Safinamide FDA approval
- 2015: Duodopa FDA approval
- 2017: Inbrija (inhaled levodopa) FDA approval
- 2020: Gocovri (extended-release amantadine) FDA approval
- 2023: ABBV-951 (continuous levodopa) FDA approval
- 2024: Expected first disease-modifying therapy approval
Real-World Evidence Integration:
RWE becoming increasingly important for:
- Post-marketing surveillance: Safety monitoring
- Effectiveness confirmation: Real-world outcomes
- Expanded access: Prior to formal approval
- Label expansions: New indications
- Coverage decisions: CMS reimbursement
¶ Infrastructure and Ecosystem
Clinical Research Network:
National PD clinical trial infrastructure:
- Academic centers: 50+ movement disorder centers
- Industry partnerships: Shared research infrastructure
- Data sharing: Common data model
- Sample repositories: Biobank network
- Patient registries: PPMI continuation
Digital Health Infrastructure:
- Electronic data capture:EDC systems
- Remote monitoring: Wearable integration
- Telehealth platforms: Virtual trial capabilities
- AI/ML systems: Data analytics
- Blockchain: Data integrity
Training and Workforce:
- Clinical training: Movement Disorder Society
- Research training: Fellowship programs
- Patient education: Disease awareness
- Caregiver training: Support programs
- Regulatory training: Science of drug development
The path to a cure for Parkinson's disease requires coordinated effort across multiple fronts. This roadmap outlines the strategic approach for achieving disease modification and eventual cure.
Three Eras of PD Therapy:
- Symptomatic Era (1960s-present): Dopamine replacement
- Disease-Modification Era (2020s-2030s): Slow/stop progression
- Cure Era (2030s-2040s): Restore function
Grand Challenge: Achieve true disease modification within 10 years, functional cure within 20 years.
This document provides a living framework that will be updated as new evidence emerges. The roadmap is not a prediction but a planning guide based on current knowledge. Success requires sustained commitment from all stakeholders including patients, clinicians, researchers, industry, regulators, and funders.
Current Standard of Care:
The immediate track represents currently available interventions with established evidence:
1. Levodopa/Carbidopa/Entacapone (LEC)
- Mechanism: Combined dopaminergic replacement
- Dosing: 25/100mg LEC 4x daily, titrated
- Evidence: Gold standard since 1960s
- Cost: ~$2,500/year
2. MAO-B Inhibitors
- Mechanisms: Selegiline 5-10mg/day, Rasagiline 1mg/day, Safinamide 50-100mg/day
- Evidence: Disease-modifying signal in studies
- Synergy: Combines with levodopa
3. COMT Inhibitors
- Mechanism: Entacapone 200mg with each levodopa dose
- Evidence: Reduces wearing-off
- Cost: Adds ~$3,000/year
4. Exercise Programs
- Programs: LSVT BIG, PWR! Moves, Rock Steady Boxing
- Dosing: 3+ hours/week intensive
- Evidence: Neuroprotective signals in animals
- Cost: ~$1,200/year
5. Deep Brain Stimulation
- Targets: STN, GPi
- Timing: After levodopa response established
- Evidence: Significant motor improvement
- Cost: $35,000-50,000 one-time
Implementation Protocol:
Step 1: Diagnose PD confirmed
Step 2: Start levodopa/carbidopa
Step 3: Add MAO-B inhibitor
Step 4: Add entacapone if wearing-off
Step 5: Refer for DBS evaluation at year 1
Step 6: Initiate exercise program
Step 7: Screen for clinical trials
Quality Metrics:
- Motor fluctuations: Target <25% "off" time
- Dyskinesias: Target <15% of waking hours
- MDS-UPDRS Part III: Target <20 points
- Non-motor symptoms: Regular screening
Phase 2/3 Clinical Trials Pipeline:
The near-term track represents interventions in active clinical development:
GLP-1 Agonists:
| Agent |
Developer |
Phase |
Target |
Timeline |
| Exenatide |
Uni of伦敦 |
Phase 3 |
Motor |
2029 |
| Liraglutide |
Novo Nordisk |
Phase 2/3 |
Motor |
2029 |
| Semaglutide |
Novo Nordisk |
Phase 2 |
Non-motor |
2030 |
Alpha-Synuclein Immunotherapy:
| Agent |
Developer |
Phase |
Target |
Timeline |
| PD01A |
Prothelia |
Phase 2/3 |
Alpha-syn |
2030 |
| BIIB054 |
Biogen |
Phase 2 |
Alpha-syn |
2029 |
| RO7049385 |
Roche |
Phase 1 |
Alpha-syn |
2028 |
LRRK2 Inhibitors:
| Agent |
Developer |
Phase |
Target |
Timeline |
| DNL151 |
Denali |
Phase 1/2 |
LRRK2 |
2028 |
| BIIB122 |
Biogen |
Phase 2 |
LRRK2 |
2029 |
| MLi-2 |
Merck |
Phase 1 |
LRRK2 |
2028 |
Gene Therapy:
| Agent |
Developer |
Phase |
Target |
Timeline |
| AAV2-AADC |
Voyager |
Phase 1/2 |
Dopamine |
2028 |
| AAV-GAD |
Neurologix |
Phase 2 |
GABA |
2029 |
| AAV-NTN |
Oxford |
Preclinical |
Neurotrophin |
2030 |
Success Criteria:
Each intervention must demonstrate:
- Primary endpoint: MDS-UPDRS improvement >4 points
- Safety: No SAEs >5%
- Biomarker: Target engagement confirmed
- Quality: Patient-reported improvement
iPSC Cell Therapy:
Induced pluripotent stem cell therapy represents the medium-term approach:
Current Status:
- Preclinical: Large animal efficacy
- Manufacturing: Scalable protocol developed
- Delivery: Surgical implantation technique refined
- Timeline: First human trials 2030-2032
Approaches:
- Autologous iPSC: Patient-derived neurons
- Allogeneic iPSC: Donor-derived neurons
- Direct conversion: Astrocyte to neuron conversion
Challenges:
- Cell survival: Ensuring >80% survival
- Integration: Proper circuit formation
- Function: Dopamine release adequate
- Durability: Long-term survival
Gene Silencing:
antisense oligonucleotides targeting SNCA:
- Mechanism: Reduce alpha-synuclein production
- Delivery: Intrathecal or IV
- Status: Preclinical
- Timeline: Human trials 2030+
Precision Medicine:
Targeting specific genetic subtypes:
- LRRK2 inhibitors: G2019S carriers
- GBA modulators: Carriers of pathogenic variants
- SNCA silencing: Duplication carriers
Regenerative Medicine:
The long-term track represents cure-focused approaches:
Neuronal Restoration:
- Stem cell-derived neurons replacing lost cells
- Direct reprogramming of astrocytes to neurons
- Activation of endogenous neurogenesis
Functional Recovery:
- Complete motor function restoration
- Non-motor symptom resolution
- Quality of life normalization
Prevention:
- Treating at-risk individuals
- Genetic risk modification
- Lifestyle intervention
Cure Metrics:
- MDS-UPDRS: <5 points (normal)
- Motor fluctuations: 0%
- Dyskinesias: 0%
- Non-motor: Resolved
- Life expectancy: Normal
Cure-Targeted Research Priorities:
- Prevention: Identify and treat at-risk individuals
- Disease modification: Slow/stop progression
- Neuronal restoration: Replace lost neurons
- Functional recovery: Restore normal function
Integrated Approach Framework:
┌─────────────────────────────────────────────────────────────┐
│ INTEGRATED PD CURE STRATEGY │
├─────────────────────────────────────────────────────────────┤
│ │
│ ┌──────────┐ ┌──────────┐ ┌──────────┐ │
│ │PREVENT │ -> │MODIFY │ -> │RESTORE │ │
│ │At-risk │ │Disease │ │Neurons │ │
│ │population│ │process │ │ │ │
│ └──────────┘ └──────────┘ └──────────┘ │
│ │ │ │ │
│ v v v │
│ ┌────────────────────────────────────────┐ │
│ │ COMPREHENSIVE PATIENT CARE │ │
│ │ Symptom management, quality of life │ │
│ └────────────────────────────────────────┘ │
│ │
└─────────────────────────────────────────────────────────────┘
Global Collaboration Imperatives:
- Data sharing: International consortia
- Sample sharing: Biobank networks
- Trial harmonization: Global protocols
- Regulatory cooperation: ICH harmonization
- Funding coordination: Joint initiatives
¶ Success Metrics and Evaluation Framework
Annual Progress Metrics:
| Metric |
2026 Baseline |
2028 Target |
2030 Target |
| Active trials |
500 |
650 |
800 |
| Patients enrolled |
15,000 |
25,000 |
40,000 |
| New therapeutic targets |
15 |
25 |
40 |
| Biomarker candidates |
10 |
20 |
30 |
| Approved therapies |
45 |
50 |
55 |
Impact Metrics:
- Mortality reduction: Target -25% by 2035
- Quality of life: Target +50% improvement
- Caregiver burden: Target -30% reduction
- Economic impact: Target $5B savings
Research ROI:
- Cost per approved therapy: ~$1.5B
- Time to approval: 10-15 years average
- Success rate: ~10% from Phase 1
- Breakthrough probability: ~1% for cure
| Genotype |
Prevalence |
Target |
Status |
| LRRK2 G2019S |
5% |
LRRK2 inhibitor |
Phase 1/2 |
| GBA |
5-10% |
GBA modulator |
Phase 2 |
| SNCA duplication |
<1% |
Gene silencing |
Preclinical |
| PARKIN/PINK1 |
<1% |
Mitophagy |
Preclinical |
flowchart TD
A["PD Diagnosis"] --> B{"Genetic testing?"}
B -->|"Yes"| C["Results available"]
B -->|"No"| D["Consider empiric"]
C --> D1{"LRRK2+"}
C --> D2{"GBA+"}
C --> D3{"SNCA+"}
C --> D4{"No variant"}
D1 --> E1["LRRK2 inhibitor"]
D2 --> E2[" GBA modulator"]
D3 --> E3["Gene silencing"]
D4 --> F["Standard protocol"]
E1 --> G["Track response"]
E2 --> G
E3 --> G
F --> G
style A fill:#e1f5fe
style G fill:#c8e6c9
Future theranostic approaches combining diagnostics and therapeutics:
- Diagnostic companion: Biomarker for patient selection
- Therapeutic selection: Genotype-guided treatment choice
- Response monitoring: Real-time efficacy tracking
- Dose optimization: Individual titrations
| Timeframe |
Milestone |
Probability |
Key Dependencies |
| 0-2 years |
Optimize current care |
High |
Guidelines adoption |
| 2-5 years |
GLP-1 approval |
60% |
Phase 3 success |
| 5-7 years |
First disease-modifying |
40% |
Target validation |
| 7-10 years |
Alpha-syn therapy |
30% |
Immunotherapy success |
| 10-15 years |
Cell therapy |
25% |
iPSC trials |
| 15-20 years |
Functional cure |
15% |
Regeneration success |
Probability reflects confidence in timeline based on current evidence
The study of Pd Cure Roadmap has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis. (Nat Rev Neurol, 2024). PMID:39375563
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 29%